|
1 |
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Enthalten in Targeted oncology 19.11.2020: 1-11
|
|
|
|
2 |
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
Enthalten in Targeted oncology 10.11.2020: 1-10
|
|
|
|
3 |
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms
Enthalten in Neuroendocrinology Bd. 107, 2018, Nr. 1: 24-31
|
|
|
4 |
The cathedral and the bazaar
Raymond, Eric S.. - Beijing : O'Reilly, 2001, Rev. ed.
|
|
|
|
5 |
The cathedral and the bazaar
Raymond, Eric S.. - Beijing : O'Reilly, 1999, 1. ed.
|
|
|
|
6 |
Learning GNU emacs
Cameron, Debra. - Bonn : O'Reilly, 1996, 2. ed., rev. & updated
|
|
|
|
7 |
Impact of the COVID-19 Outbreak on the Management of Patients with Cancer
Enthalten in Targeted oncology Bd. 15, 22.5.2020, Nr. 3, date:6.2020: 249-259
|
|
|
|
8 |
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
Enthalten in Journal of translational medicine Bd. 9, 25.7.2011, Nr. 1, date:12.2011: 1-14
|
|
|
|
9 |
Sunitinib paves the way for targeted therapies in neuroendocrine tumors
Enthalten in Targeted oncology Bd. 4, 13.11.2009, Nr. 4, date:12.2009: 253-254
|
|
|
10 |
Raymond, Eric S.
1957- / Informatiker
|
|
Administration
